
Progress in Mind
Clinicians value biomarkers when assessing mild cognitive impairment (MCI) but are less certain about how best to discuss their implications with patients.
Tau-PET imaging in the clinic is on the horizon and would complement amyloid-PET and structural and functional MRI in our search for tools in the differential diagnosis and staging of demen